JP2006512284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006512284A5 JP2006512284A5 JP2004508113A JP2004508113A JP2006512284A5 JP 2006512284 A5 JP2006512284 A5 JP 2006512284A5 JP 2004508113 A JP2004508113 A JP 2004508113A JP 2004508113 A JP2004508113 A JP 2004508113A JP 2006512284 A5 JP2006512284 A5 JP 2006512284A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- use according
- nucleus
- nucleic acid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 claims 36
- 210000004027 cell Anatomy 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 230000010076 replication Effects 0.000 claims 13
- 108010049024 Viral Oncogene Proteins Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 108700020796 Oncogene Proteins 0.000 claims 9
- 108700019146 Transgenes Proteins 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 7
- 241000701161 unidentified adenovirus Species 0.000 claims 6
- 102000043276 Oncogene Human genes 0.000 claims 5
- 108700005077 Viral Genes Proteins 0.000 claims 5
- 230000004913 activation Effects 0.000 claims 5
- 238000012217 deletion Methods 0.000 claims 5
- 230000037430 deletion Effects 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 108091023037 Aptamer Proteins 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000000824 cytostatic agent Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 230000029812 viral genome replication Effects 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 claims 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 claims 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 claims 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 claims 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 108010063312 Metalloproteins Proteins 0.000 claims 1
- 102000010750 Metalloproteins Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 1
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 1
- 230000002424 anti-apoptotic effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000030648 nucleus localization Effects 0.000 claims 1
- 108091008819 oncoproteins Proteins 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2002123534 DE10223534A1 (de) | 2002-05-27 | 2002-05-27 | Verwendung von Adenoviren und dafür codierenden Nukleinsäuren |
| DE10223534.1 | 2002-05-27 | ||
| DE10225400.1 | 2002-06-07 | ||
| DE10225400 | 2002-06-07 | ||
| DE10248039 | 2002-10-15 | ||
| DE10248039.7 | 2002-10-15 | ||
| DE10322530 | 2003-05-19 | ||
| DE10322530.7 | 2003-05-19 | ||
| PCT/EP2003/005583 WO2003099859A2 (de) | 2002-05-27 | 2003-05-27 | Neue verwendung von adenoviren und dafür codierenden nukleinsäuren |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116438A Division JP5719800B2 (ja) | 2002-05-27 | 2012-05-22 | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006512284A JP2006512284A (ja) | 2006-04-13 |
| JP2006512284A5 true JP2006512284A5 (enExample) | 2006-07-06 |
| JP5213298B2 JP5213298B2 (ja) | 2013-06-19 |
Family
ID=29587746
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004508113A Expired - Lifetime JP5213298B2 (ja) | 2002-05-27 | 2003-05-27 | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
| JP2012116438A Expired - Lifetime JP5719800B2 (ja) | 2002-05-27 | 2012-05-22 | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
| JP2014158673A Withdrawn JP2014224141A (ja) | 2002-05-27 | 2014-08-04 | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116438A Expired - Lifetime JP5719800B2 (ja) | 2002-05-27 | 2012-05-22 | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
| JP2014158673A Withdrawn JP2014224141A (ja) | 2002-05-27 | 2014-08-04 | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20060099178A1 (enExample) |
| EP (1) | EP1506021B1 (enExample) |
| JP (3) | JP5213298B2 (enExample) |
| KR (1) | KR101083450B1 (enExample) |
| CN (2) | CN1655827B (enExample) |
| AU (2) | AU2003242585A1 (enExample) |
| CA (1) | CA2487811A1 (enExample) |
| WO (1) | WO2003099859A2 (enExample) |
| ZA (1) | ZA200409361B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1655827B (zh) | 2002-05-27 | 2010-06-23 | 佩尔·松内·霍尔姆 | 腺病毒和编码其的核酸的新应用 |
| US20060270016A1 (en) * | 2003-11-14 | 2006-11-30 | Holm Per S | Novel adenoviruses, nucleic acids that code for the same and the use of said viruses |
| WO2005051430A1 (de) * | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierenden nukleinsäuren |
| US8361976B2 (en) | 2004-07-09 | 2013-01-29 | University Of Massachusetts | Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules |
| AU2006203736B2 (en) * | 2004-12-31 | 2012-03-29 | Per Sonne Holm | Method for reversing multiple resistance in animal cells |
| EP1830864A2 (de) * | 2004-12-31 | 2007-09-12 | Per Sonne Holm | E1 -minus adenoviren und deren verwendung |
| WO2012022496A2 (en) | 2010-08-19 | 2012-02-23 | Per Sonne Holm | Method for killing tumor stem cells |
| CA2903582C (en) * | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CA3092907A1 (en) | 2018-03-05 | 2019-09-12 | Klinikum Rechts Der Isar Der Technischen Universitat Munchen | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| EP3810638A1 (en) * | 2018-06-25 | 2021-04-28 | Ospedale San Raffaele S.r.l. | Gene therapy |
| US20220354911A1 (en) | 2019-09-05 | 2022-11-10 | Klinikum Rechts Der Isar Der Technischen Universität München | Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent |
| EP4123021A4 (en) * | 2020-03-23 | 2024-05-15 | Curigin Co.,Ltd. | Structure of oncolytic virus comprising bispecific nucleic acid molecule |
| CN114540349B (zh) * | 2020-11-27 | 2024-11-22 | 中国科学院分子细胞科学卓越创新中心 | 结合yb-1蛋白的核酸分子 |
| EP4404947A4 (en) | 2021-09-23 | 2025-12-10 | Sagittarius Bio Inc | Adenovirus and Methods of Using Adenovirus |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US931830A (en) * | 1907-09-17 | 1909-08-24 | Harry Zimmerman | Material-cutter. |
| US4947842A (en) | 1988-09-22 | 1990-08-14 | Medical Engineering And Development Institute, Inc. | Method and apparatus for treating tissue with first and second modalities |
| KR970002255B1 (ko) | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
| PT931830E (pt) | 1993-02-16 | 2001-08-30 | Onyx Pharma Inc | Virus citopaticos para terapia e profilaxia de neoplasia |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6326356B1 (en) * | 1996-10-18 | 2001-12-04 | Board Of Regents, The University Of Texas System | Suppression of neu overexpression using a mini-E1A gene |
| JP3827163B2 (ja) | 1995-03-24 | 2006-09-27 | ジェンザイム・コーポレーション | 遺伝子治療用のアデノウイルスベクター |
| US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
| US6676935B2 (en) | 1995-06-27 | 2004-01-13 | Cell Genesys, Inc. | Tissue specific adenoviral vectors |
| WO1997016547A1 (en) | 1995-10-31 | 1997-05-09 | The Board Of Regents, The University Of Texas System | ADENOVIRUS-ANTISENSE K-ras EXPRESSION VECTORS AND THEIR APPLICATION IN CANCER THERAPY |
| US6022863A (en) | 1996-05-21 | 2000-02-08 | Yale University | Regulation of gene expression |
| CA2259152C (en) | 1996-07-05 | 2002-02-12 | Philip E. Branton | Adenovirus e4 proteins for inducing cell death |
| US6730662B1 (en) * | 1996-07-05 | 2004-05-04 | Mcgill University | Adenovirus E4 proteins for inducing cell death |
| JP2001504448A (ja) | 1996-08-30 | 2001-04-03 | フュルステ，イェンス，ペーター | 核酸の鏡面対称選択および進化 |
| US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
| AU5253998A (en) | 1996-11-13 | 1998-06-03 | Board Of Regents, The University Of Texas System | Diminishing viral gene expression by promoter replacement |
| US6080578A (en) | 1996-12-31 | 2000-06-27 | Onyx Pharmaceuticals, Inc. | Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia |
| US6100086A (en) | 1997-04-14 | 2000-08-08 | Genzyme Corporation | Transgene expression systems |
| EP1002103B1 (en) | 1997-08-04 | 2007-10-17 | Cell Genesys, Inc. | A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| NZ518945A (en) | 1997-10-09 | 2007-03-30 | Wellstat Biologics Corp | Treatment of neoplasms with viruses |
| CN1110553C (zh) * | 1998-07-15 | 2003-06-04 | 杭州赛狮生物技术开发有限公司 | 基因工程腺病毒及其用途 |
| CA2345211A1 (en) | 1998-10-15 | 2000-04-20 | John A. Howe | Recombinant e1a deleted adenoviral vectors |
| US6649158B1 (en) | 1998-10-15 | 2003-11-18 | Canji, Inc. | Methods and compositions to induce antitumor response |
| DE19860602A1 (de) | 1998-12-29 | 2000-07-06 | Max Delbrueck Centrum | Gentransfervektor für die Diagnostik und die Therapie von malignen Tumoren |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| GB9906815D0 (en) | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
| DE19929569A1 (de) | 1999-06-21 | 2000-12-28 | Holm Per Sonne | Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1 |
| AU6425800A (en) | 1999-06-30 | 2001-01-22 | Max-Delbruck-Centrum Fur Molekulare Medizin | Agents for the diagnosis, prognosis and treatment of malignant diseases |
| US6955808B2 (en) | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
| US6635476B1 (en) * | 1999-10-15 | 2003-10-21 | Canji, Inc. | Targeted vectors |
| US6140126A (en) | 1999-10-26 | 2000-10-31 | Isis Pharmaceuticals Inc. | Antisense modulation of Y-box binding protein 1 expression |
| US7001596B1 (en) * | 1999-11-15 | 2006-02-21 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| DE10015413A1 (de) | 2000-03-23 | 2001-09-27 | Max Delbrueck Centrum | Mittel zur Diagnose und Therapie viraler Erkrankungen |
| EP1301612A2 (en) | 2000-05-31 | 2003-04-16 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| AU784975B2 (en) | 2000-10-11 | 2006-08-10 | Sumitomo Chemical Company, Limited | DNA-binding protein YB-1-containing collagen accumulation inhibitors |
| AU2002235141A1 (en) | 2000-11-27 | 2002-06-03 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
| US20030095989A1 (en) | 2000-12-18 | 2003-05-22 | Irving John M. | Chimeric cytolytic viruses for cancer treatment |
| AU2002229679B2 (en) | 2000-12-28 | 2007-12-20 | Per Sonne Holm | Use of transcription factor YB-1 in adenoviral systems |
| DE10150945A1 (de) | 2001-10-16 | 2003-04-17 | Holm Per Sonne | Adenovirale Systeme und deren Anwendungen |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| WO2003025190A1 (en) | 2001-09-14 | 2003-03-27 | The New Industry Research Organization | Tumor-specific promoter and use thereof |
| DE10150984A1 (de) | 2001-10-16 | 2003-04-17 | Holm Per Sonne | Verwendung des adenoviralen E2-late-Promotors |
| WO2004001032A2 (en) | 2002-04-25 | 2003-12-31 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| CN1655827B (zh) | 2002-05-27 | 2010-06-23 | 佩尔·松内·霍尔姆 | 腺病毒和编码其的核酸的新应用 |
| US8951772B2 (en) * | 2002-10-15 | 2015-02-10 | Per Sonne Holm | Adenoviruses, nucleic acids coding therefor, and use thereof |
| JP4988199B2 (ja) | 2002-10-15 | 2012-08-01 | ホルム，ペル・ゾンネ | 新規アデノウイルス、それをコードする核酸及びその使用 |
| CA2522380A1 (en) | 2003-03-19 | 2004-09-30 | Isogenis, Inc. | Specific inhibition of allorejection |
| WO2005051430A1 (de) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierenden nukleinsäuren |
| US20060270016A1 (en) | 2003-11-14 | 2006-11-30 | Holm Per S | Novel adenoviruses, nucleic acids that code for the same and the use of said viruses |
| JP4621743B2 (ja) | 2004-12-13 | 2011-01-26 | カンジ，インコーポレイテッド | 複製欠損アデノウイルスの産生のための細胞株 |
| AU2006203736B2 (en) | 2004-12-31 | 2012-03-29 | Per Sonne Holm | Method for reversing multiple resistance in animal cells |
| EP1830864A2 (de) | 2004-12-31 | 2007-09-12 | Per Sonne Holm | E1 -minus adenoviren und deren verwendung |
| US20070292396A1 (en) | 2006-03-02 | 2007-12-20 | Juan Fueyo | Combination therapy with oncolytic adenovirus |
-
2003
- 2003-05-27 CN CN03812310XA patent/CN1655827B/zh not_active Expired - Fee Related
- 2003-05-27 EP EP03755145.4A patent/EP1506021B1/de not_active Expired - Lifetime
- 2003-05-27 US US10/515,238 patent/US20060099178A1/en not_active Abandoned
- 2003-05-27 KR KR1020047019231A patent/KR101083450B1/ko not_active Expired - Fee Related
- 2003-05-27 JP JP2004508113A patent/JP5213298B2/ja not_active Expired - Lifetime
- 2003-05-27 CA CA002487811A patent/CA2487811A1/en not_active Abandoned
- 2003-05-27 CN CN201010161559.4A patent/CN101843641B/zh not_active Expired - Fee Related
- 2003-05-27 WO PCT/EP2003/005583 patent/WO2003099859A2/de not_active Ceased
- 2003-05-27 AU AU2003242585A patent/AU2003242585A1/en not_active Abandoned
-
2004
- 2004-11-22 ZA ZA2004/09361A patent/ZA200409361B/en unknown
-
2010
- 2010-04-28 US US12/769,435 patent/US10155930B2/en not_active Expired - Lifetime
- 2010-09-09 AU AU2010219364A patent/AU2010219364B2/en not_active Ceased
-
2012
- 2012-05-22 JP JP2012116438A patent/JP5719800B2/ja not_active Expired - Lifetime
-
2014
- 2014-08-04 JP JP2014158673A patent/JP2014224141A/ja not_active Withdrawn
-
2017
- 2017-03-07 US US15/452,470 patent/US10538744B2/en not_active Expired - Fee Related
-
2018
- 2018-10-31 US US16/176,461 patent/US10731136B2/en not_active Expired - Fee Related
-
2019
- 2019-12-05 US US16/704,669 patent/US11268073B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006512284A5 (enExample) | ||
| US11268073B2 (en) | Use of adenovirus and nucleic acids coding therefor | |
| JP5618896B2 (ja) | 新規アデノウイルス、それをコードする核酸及びその使用 | |
| Zhu et al. | Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo | |
| JP2021097701A (ja) | 内皮特異的核酸調節エレメントならびにその方法および使用 | |
| JP2008526188A5 (enExample) | ||
| JP2019520814A5 (enExample) | ||
| JP5435871B2 (ja) | Ｅ１−マイナスアデノウイルス及びその使用 | |
| JP2008526189A5 (enExample) | ||
| JP2008526188A (ja) | 動物細胞における多剤耐性を逆転させる方法 | |
| US12371670B2 (en) | Fast and accurate three-plasmid oncolytic adenovirus recombinant packaging system Ad5MixPlus and application thereof | |
| Chang et al. | Durable expression of minicircle DNA‐liposome‐delivered androgen receptor cDNA in mice with hepatocellular carcinoma | |
| RU2005114516A (ru) | Аденовирус с обращенной генной экспрессией и его применение | |
| JP2006518589A5 (enExample) | ||
| Wu et al. | Augmenter of liver regeneration gene therapy using a novel minicircle DNA vector alleviates liver fibrosis in rats | |
| Sonabend et al. | Oncolytic adenoviral therapy for glioblastoma multiforme | |
| Iizuka et al. | Evaluation of transduction properties of an adenovirus vector in neonatal mice | |
| JP2005505299A (ja) | アデノウイルスｅ２後期プロモーターの使用 | |
| RU2522810C1 (ru) | Носитель для направленной доставки нуклеиновых кислот в клетки, экспрессирующие рецептор cxcr4 | |
| RU2004138095A (ru) | Новое применение аденовируса и кодирующих его нуклеиновых кислот | |
| JP2005530495A (ja) | オールターナティブスプライシングされる核酸分子 | |
| Braden et al. | Polymeric nanoparticles for sustained down-regulation of annexin A2 lead to reduction in proliferation and migration of prostate cancer cells | |
| AU2015201828B2 (en) | Novel use of adenoviruses and nucleic acids coding therefor | |
| CN1705740B (zh) | 具有反向基因表达的腺病毒及其应用 | |
| Vonka | Gene Therapy: Hopes and Problems |